drugset / Trial / NCT04495179
A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II, international, open-label, two-arm, non-randomised study of AZD4635 in participants with metastatic castration-resistant prostate cancer (mCRPC).
Timeline
- Start
- 2020-08-04
- Primary completion
- 2021-11-01
- Completion
- 2022-08-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabazitaxel | Other / unclassified | — | Intravenous |
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | imaradenant | Small molecule | — | Oral |